everything.study
HST.151

Principles of Pharmacology

5-0-7 units · Graduate

Covers both general pharmacological principles (pharmacodynamics, toxicology, pharmacokinetics, pharmacogenetics, drug interactions, pharmacoepidemiology, pharmaco-economics, and the placebo effect), and important clinical pharmacology areas (anti-microbials, general anesthetics, local anesthetics, autonomic modulation, anti-dysrhythmics, hypertension, heart failure, diabetes, anti-inflammatory drugs for rheumatology, immunomodulation for organ transplant, cancer chemotherapy, neuropsychopharmacology, opioids and opioid use disorder, cannabinoids, and drug delivery engineering). In addition, students taking the subject for credit contribute to teaching by presenting and analyzing clinical cases and therapeutic strategies. Highly recommended that students have prior education in human physiology and pathophysiology. Subject follows HMS calendar. Restricted to HST MD & HST PhD students.

Spring 2005

The object of the course is to teach students an approach to the study of pharmacologic agents. It is not intended to be a review of the pharmacopoeia. The focus is on the basic principles of biophysics, biochemistry and physiology, as related to the mechanisms of drug action, biodistribution and metabolism. The course consists of lectures and student-led case discussions. Topics covered include: mechanisms of drug action, dose-response relations, pharmacokinetics, drug delivery systems, drug metabolism, toxicity of pharmacological agents, drug interaction and substance abuse. Selected agents and classes of agents are examined in detail.

Readings

  • Readings for this course consist of the textbook, optional papers, and some suggested supplemental sources.
    Listed reading
  • Textbook readings listed are in the course textbook:
    Listed reading
  • Golan, D., et. al., eds. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy . Philadelphia, PA: Lippincott Williams and Wilkins, 2004. ISBN: 9780781746786.
    Listed reading
  • pp. 55-106, and 724-725 Bernard, G. R., et. al. “Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis.” The New England Journal of Medicine 344, no. 10 (2001): 699-709.
    Listed reading
  • pp. 205-228, 121-136, 267-284, and 719-743 Buxton, Alfred E., et. al. “A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease.” The New England Journal of Medicine 341, no. 25 (1999): 1882-1890.
    Listed reading
  • pp. 781-787, and 617-646 Weinblatt, Michael E., et. al. “A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate.” The New England Journal of Medicine 340, no. 4 (1999): 253-259.
    Listed reading
  • Edwards, David A., et. al. “Large Porous Particles for Pulmonary Drug Delivery.” Science 276, no. 5320 (1997): 1868-1871.
    Listed reading
  • Langer, Robert J. “New Methods of Drug Delivery.” Science 249, no. 4976 (1990): 1527-1533.
    Listed reading
  • pp. 285-333, 375-399, and 415-424 Wing, Lindon M. H., et. al. “A Comparison of Outcomes with Angiotensin-converting-enzyme Inhibitors and Diuretics for Hypertension in the Elderly.” The New England Journal of Medicine 348, no. 7 (2003): 583-592.
    Listed reading
  • The Digitalis Investigation Group. “The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure.” The New England Journal of Medicine 336, no. 8 (1997): 525-533.
    Listed reading
  • pp. 357-374, 447, and 709-715 Knopp, Robert H. “Drug Treatment of Lipid Disorders.” The New England Journal of Medicine 341, no. 7 (1999): 498-511.
    Listed reading
  • pp. 647-654, 683-694, and 667-681 Simons, F. Estelle R. “Advances in H1-Antihistamines.” The New England Journal of Medicine 351, no. 21 (2004): 2203-2217.
    Listed reading
  • LEC #: 11 · TOPICS: Drug Development · TEXTBOOK READINGS: pp. 747-756, and 791-801 · optional PAPERS: Lazo, John S., and Peter Wipf. “Combinatorial Chemistry and Contemporary Pharmacology.” The Journal of Pharmacology and Experimental Therapeutics 298, no. 8 (2000): 705-709.
    Reading assignment
  • pp. 161-178, and 40 Ichinose, Fumito, Jesse D. Roberts, Jr., and Warren M. Zapol. “Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator: Current Uses and Therapeutic Potential.” Circulation 109, no. 25 (2004): 3106-3111.
    Listed reading
  • Steudel, Wolfgang, William E. Hurford, and Warren M. Zapol. “Inhaled Nitric Oxide: Basic Biology and Clinical Applications.” Anesthesiology 91, no. 4 (1990): 1090-1121.
    Listed reading
  • pp. 493-504, 535-544, 565-578, and 603-613 Rodvold, Keith A. “Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient’s Bedside.” Pharmacotherapy 21, no. 11, Pt 2 (2001): 319S - 330S.
    Listed reading
  • pp. 229-263 Kieffer, B. L. “Opioids: First Lessons from Knockout Mice.” Trends in Pharmacological Sciences 20, no. 1 (1999): 19-26.
    Listed reading
  • Hardman, J. G., et. al., eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics . 10th ed. New York, NY: McGraw-Hill, 2001. ISBN: 9780071354691.
    Listed reading
  • Katzung, B., et. al., eds. Basic and Clinical Pharmacology . 9th ed. New York, NY: McGraw-Hill, 2003. ISBN: 9780071410922.
    Listed reading

Prerequisites & course information

Subject meets with HST.150 Prereq: Biology (GIR) , Physics I (GIR) , and 7.05 G (Fall) 5-0-7 units

Sources